Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial

CONTEXT: Long-acting recombinant human growth hormone (rhGH) has transformed growth hormone deficiency (GHD) treatment. However, the possibility and rationality for flexible time regimen are pending. OBJECTIVE: We studied the efficacy of biweekly versus weekly PEGylated rhGH (PEG-rhGH) therapy in GH...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Chengjun, Lu, Biao, Liu, Yu, Zhang, Yaqin, Wei, Haiyan, Hu, Xu, Hu, Pei, Zhao, Qian, Liu, Yanling, Ye, Kan, Wang, Kan, Gu, Zaiyan, Liu, Zheng, Ye, Jin, Zhang, Hongxiao, Zhu, Hong, Jiang, Zhihong, Liu, Yanjie, Wan, Naijun, Yan, Chengming, Yin, Jianying, Ying, Lirong, Huang, Feng, Yin, Qingjin, Xi, Li, Luo, Feihong, Cheng, Ruoqian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655095/
https://www.ncbi.nlm.nih.gov/pubmed/34899612
http://dx.doi.org/10.3389/fendo.2021.779365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655095/
https://www.ncbi.nlm.nih.gov/pubmed/34899612
http://dx.doi.org/10.3389/fendo.2021.779365

Ejemplares similares